PDSB (pdsbiotech.com) חוב לטווח ארוך

This price chart for PDS Biotechnology (PDSB) reflects the price action of a biotech developer creating methods to combat HPV tumors by training the body to locate metastases. The company's operations rely on targeted medicine and the successful completion of medical trials. The current debt load stands at 0.00, which is typical for the research investment stage in the absence of commercial sales and amid rising costs.

The development of the Versamune platform and patient retention in clinical phases require significant funding to ensure therapy safety. This indicator aggregates obligations with maturities exceeding one year, reflecting the long-term credit load and the pace of borrowed capital utilization, which allows investors to assess the financial stability of PDS Biotechnology (PDSB) through the volume of the corporation's long-term loans and borrowings.